Potential Efficacy of Proteasome Inhibitor, Delanzomib, for the Treatment of Renal Fibrosis
Biological and Pharmaceutical Bulletin · 2023
DOI: 10.1248/bpb.b22-00713 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biological and Pharmaceutical Bulletin, 2023. Verfasst von Ayano Sawa-Aihara und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacokinetics and Biopharmaceutics, Institute of Biomedical Sciences, Tokushima University. Hauptthemen laut MEDLINE: Proteasome Inhibitors, Kidney Diseases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 42 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacokinetics and Biopharmaceutics, Institute of Biomedical Sciences, Tokushima University.
- Department of Renal and Cardiovascular Research, Otsuka Pharmaceutical Co., Ltd.
Zitieren
APA
Sawa-Aihara, A., Hattori, K., Nagao, G., Yamada, Y., & Ishida, T. (2023). Potential Efficacy of Proteasome Inhibitor, Delanzomib, for the Treatment of Renal Fibrosis. Biological and Pharmaceutical Bulletin. https://doi.org/10.1248/bpb.b22-00713
Vancouver
Sawa-Aihara A, Hattori K, Nagao G, Yamada Y, Ishida T. Potential Efficacy of Proteasome Inhibitor, Delanzomib, for the Treatment of Renal Fibrosis. Biological and Pharmaceutical Bulletin. 2023. doi:10.1248/bpb.b22-00713
BibTeX
@article{SawaAihara2023,
author = {Sawa-Aihara, Ayano and Hattori, Katsuji and Nagao, Goshi and Yamada, Yoshihisa and Ishida, Tatsuhiro},
title = {Potential Efficacy of Proteasome Inhibitor, Delanzomib, for the Treatment of Renal Fibrosis},
journal = {Biological and Pharmaceutical Bulletin},
year = {2023},
doi = {10.1248/bpb.b22-00713}
}
EUVIMED